Skip to main content

NASDAQ:INMD - InMode Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $80.25
  • Forecasted Upside: 4.13 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$77.07
▲ +1.72 (2.28%)
1 month | 3 months | 12 months
Get New InMode Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INMD

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$80.25
▲ +4.13% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for InMode in the last 3 months. The average price target is $80.25, with a high forecast of $104.00 and a low forecast of $38.00. The average price target represents a 4.13% upside from the last price of $77.07.

Buy

The current consensus among 4 polled investment analysts is to buy stock in InMode.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/16/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/14/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/12/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/10/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/8/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/9/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/6/2021Canaccord GenuityBoost Price TargetBuy$80.00 ➝ $95.00High
i
5/6/2021Robert W. BairdBoost Price TargetOutperform$84.00 ➝ $104.00High
i
2/11/2021Robert W. BairdBoost Price TargetOutperform$58.00 ➝ $84.00Low
i
2/11/2021Canaccord GenuityBoost Price TargetBuy$69.00 ➝ $80.00Low
i
2/11/2021UBS GroupBoost Price TargetBuy$64.00 ➝ $84.00Low
i
10/21/2020Canaccord GenuityBoost Price TargetBuy$42.00 ➝ $51.00Medium
i
10/14/2020UBS GroupBoost Price TargetBuy$43.00 ➝ $47.00High
i
10/13/2020Robert W. BairdBoost Price TargetOutperform$43.00 ➝ $55.00High
i
8/17/2020BarclaysBoost Price TargetOverweight$36.00 ➝ $38.00High
i
5/7/2020Canaccord GenuityLower Price TargetBuy$50.00 ➝ $40.00Low
i
5/7/2020UBS GroupLower Price TargetBuy$46.00 ➝ $42.00Low
i
3/26/2020BarclaysLower Price TargetOverweight$48.00 ➝ $36.00Low
i
2/19/2020BarclaysBoost Price TargetOverweight$45.00 ➝ $48.00High
i
2/19/2020Canaccord GenuityReiterated RatingBuy$50.00High
i
1/28/2020Robert W. BairdReiterated RatingOutperform$45.00 ➝ $55.00Medium
i
Rating by Jeff Johnson at Robert W. Baird
11/6/2019BarclaysBoost Price TargetOverweight$27.00 ➝ $45.00High
i
11/6/2019Robert W. BairdReiterated RatingOutperform$27.00 ➝ $45.00High
i
Rating by Jeff Johnson at Robert W. Baird
9/3/2019BarclaysInitiated CoverageOverweight$27.00High
i
9/3/2019Robert W. BairdInitiated CoverageOutperform$27.00High
i
9/3/2019Canaccord GenuityInitiated CoverageBuy$30.00High
i
9/3/2019UBS GroupInitiated CoverageBuy$28.00High
i
(Data available from 5/9/2016 forward)
InMode logo
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Read More

Today's Range

Now: $77.07
$76.12
$79.59

50 Day Range

MA: $79.74
$66.90
$90.06

52 Week Range

Now: $77.07
$21.68
$92.38

Volume

732,675 shs

Average Volume

757,159 shs

Market Capitalization

$2.46 billion

P/E Ratio

55.45

Dividend Yield

N/A

Beta

1.95

Frequently Asked Questions

What sell-side analysts currently cover shares of InMode?

The following Wall Street research analysts have issued stock ratings on InMode in the last year: Barclays PLC, Canaccord Genuity, Robert W. Baird, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for INMD.

What is the current price target for InMode?

4 Wall Street analysts have set twelve-month price targets for InMode in the last year. Their average twelve-month price target is $80.25, suggesting a possible upside of 4.1%. Robert W. Baird has the highest price target set, predicting INMD will reach $104.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $38.00 for InMode in the next year.
View the latest price targets for INMD.

What is the current consensus analyst rating for InMode?

InMode currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INMD will outperform the market and that investors should add to their positions of InMode.
View the latest ratings for INMD.

What other companies compete with InMode?

How do I contact InMode's investor relations team?

InMode's physical mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The healthcare company's listed phone number is 972-4909-6313 and its investor relations email address is [email protected] The official website for InMode is www.inmodemd.com.